Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
Cantor Fitzgerald
Covington
US Army
Deloitte

Generated: August 24, 2019

DrugPatentWatch Database Preview

Litigation Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Docket ➤ Sign Up Date Filed 2017-06-01
Court District Court, D. Delaware Date Terminated 2019-03-11
Cause 35:271 Patent Infringement Assigned To Joseph F. Bataillon
Jury Demand None Referred To Sherry R. Fallon
Parties ALLERGAN, INC.; ALMIRALL LLC; TARO PHARMACEUTICAL INDUSTRIES LTD.; TARO PHARMACEUTICALS, INC.
Patents 9,517,219
Attorneys Anthony David Raucci; Chanson Chang; David A. Bilson; Elizabeth B. Hagan; Elizabeth Hagan; Ewa M. Davison; Jack B. Blumenfeld; James S. Trainor , Jr.; Jeremy A. Tigan; John C. Phillips , Jr.; Kevin X. McGann; Kimberly A. Beis; Maryellen Noreika; Matthew M. Holub; Rebecca A.E. Fewkes; Stephen P. Benson; Vanessa Park-Thompson
Firms Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket External link to docket
Small Molecule Drugs cited in Almirall LLC v. Taro Pharmaceutical Industries Ltd.
The small molecule drug covered by the patent cited in this case is ➤ Sign Up .

Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 113 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2 . (Blumenfeld, Jack…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 137 would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least External link to document
0000-00-00 39 infringement of United States Patent No. 9,517,219 ("the '219 patent"), which is entitled …;Allergan") brought this civil action for patent infringement under the Hatch-Waxman Act on June…for Use Thereof. (D.I. 1 at if 18) The '219 patent encompasses the approved use of Allergan's …prosecution of the application leading to the '219 patent, which allegedly limited the claimed polymeric…multi-component PVB and the claimed PVB in the '219 patent is the proper subject of fact and expert discovery External link to document
0000-00-00 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2. (nmg) (Entered:…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 87 Report and Recommendations alleges infringement of U.S. Patent No. 9,517,219 ("the '219 patent") under the doctrine …#39;219 patent. However, Allergan alleges that Taro's product infringes the '219 patent through…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…the '219 patent claims a PVB "comprising [A/SA] copolymer." ('219 patent, col. 16:8-10… 7 '219 patent over the prior art by explaining that the '219 patent employs an A/SA copolymer External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
Cipla
Fish and Richardson
Deloitte
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.